Last updated: February 26, 2026
What is Renflexis?
Renflexis is a biosimilar of infliximab, developed by Samsung Bioepis and marketed by Merck (MSD). It is used to treat autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis. The drug contains a recombinant monoclonal antibody that inhibits tumor necrosis factor alpha (TNFα).
What are the key excipients in Renflexis?
Renflexis formulation comprises several excipients to ensure stability, solubility, and bioavailability. The main excipients include:
- Sodium chloride: Maintains isotonicity.
- Sodium phosphate (dibasic and monobasic): Buffering agent to maintain pH.
- Sorbitol: Stabilizer and tonicity agent.
- Polysorbate 80: Surfactant to prevent aggregation.
- Water for injection: Solvent for the formulation.
These excipients are standard in monoclonal antibody formulations, with no specialized or proprietary excipients reported for Renflexis.
How does the excipient profile compare to originator infliximab?
Original infliximab (Remicade) contains similar excipients, including sodium chloride, sodium phosphate buffers, and polysorbate 80. The biosimilar uses a comparable excipient composition to match the reference product’s stability profile and ensure similar pharmacokinetics.
Excipient strategy considerations
1. Regulatory compliance
Developers maintain excipient composition consistent with the reference infliximab to secure regulatory approval and ease comparability. Regulatory agencies (FDA, EMA) focus on excipients that influence immunogenicity and stability.
2. Stability and shelf-life
Sorbitol and polysorbate 80 stabilize the protein against aggregation. Adjusting excipient levels can extend shelf life. For biosimilars, matching the reference’s excipient profile simplifies approval and reduces development risk.
3. Immunogenicity risk
Excipients like polysorbate 80 are scrutinized for potential hypersensitivity. Modulating excipient levels may reduce adverse immune responses; however, standard formulations are preferred to maintain proven safety profiles.
4. Compatibility with delivery methods
Renflexis is administered via intravenous infusion. Excipients must maintain stability in pre-filled syringes and infusion bags. Compatibility with infusion materials influences excipient choice.
Commercial opportunities linked to excipient strategy
1. Cost management
Using existing, approved excipients minimizes manufacturing complexity and regulatory delays. Cost-effective excipient sources can lower production costs, enabling competitive pricing.
2. Patent and exclusivity considerations
Excipients are generally not patentable unless proprietary or novel formulations. Developing unique excipients or delivery systems can create patent barriers, extending product exclusivity.
3. Lifecycle extension
Modifying excipients or formulation (e.g., adding stabilizers or preservatives) can improve stability, allowing for longer shelf life or alternative delivery routes. These modifications can create secondary patent opportunities.
4. Differentiation via formulation
Formulation innovations, such as extended stability or reduced infusion volume, can serve as differentiators. This enables premium pricing or expanded access, especially in hospital settings where infusion time is critical.
5. Market expansion
Formulations with improved stability or ease of use facilitate global distribution, especially in regions with limited cold chain infrastructure. Excipients that improve stability at ambient conditions expand market reach.
Strategic considerations
- Regulatory alignment: Matching the reference product's excipients simplifies approval.
- Manufacturing scalability: Using common excipients benefits from existing supply chains.
- Patent landscape: While excipients are typically unpatented, optimizing formulations can provide licensing opportunities.
- Innovation potential: Incorporation of novel or multifunctional excipients offers avenues for differentiation but requires extensive validation.
Key challenges
- Maintaining immunogenicity and stability while altering excipients.
- Regulatory constraints on excipient safety profiles.
- Market acceptance of formulation changes or improvements.
Conclusion
Renflexis's excipient strategy prioritizes matching reference products to streamline approval and reduce costs. Commercial opportunities hinge on optimizing excipient usage for stability, cost, and market differentiation. Innovation in excipient formulation remains a potential avenue for expanding lifecycle and market reach.
Key Takeaways
- Renflexis uses standard excipients similar to its reference, infliximab.
- Excipients are selected for stability, regulatory approval, and infusion compatibility.
- Cost efficiency and patent strategies favor the use of known excipients.
- Formulation modifications can extend product lifecycle and market reach.
- Innovations in excipients or delivery methods may create new commercial opportunities.
5 FAQs
Q1: Can changing excipients improve Renflexis’s stability?
Yes. Modifying or optimizing excipient levels can enhance stability, extend shelf life, or enable new formulations.
Q2: Are proprietary excipients used in Renflexis?
No. Renflexis primarily uses standard excipients widely accepted in monoclonal antibody formulations.
Q3: How do excipients affect regulatory approval?
Regulators assess excipients for safety, immunogenicity, and consistency. Matching reference product excipients simplifies approval pathways.
Q4: What role do excipients play in biosimilar differentiation?
While they primarily ensure safety and stability, innovative excipient choices can improve patient convenience or product handling, creating competitive advantages.
Q5: Are there patent opportunities related to excipient formulation?
Generally, excipients themselves are not patentable unless novel or proprietary. Formulation innovations or delivery systems can provide patent opportunities.
References
[1] Food and Drug Administration. (2020). Biosimilar Development and Approval. https://www.fda.gov/drugs/biosimilars/biosimilar-development-approval
[2] European Medicines Agency. (2018). Biosimilars: Reflection Paper. https://www.ema.europa.eu/en/documents/scientific-guideline/biosimilars-reflection-paper_en.pdf
[3] Lee, J., & Kim, D. (2022). Formulation strategies for monoclonal antibody biosimilars. Journal of Pharmaceutical Sciences, 111(2), 541-556.
